The NeurologyLive® epilepsy clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to epilepsy and related epileptic conditions, including Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, focal seizures, nonmotor seizures, and more.
Check out some of NeurologyLive®'s featured content in the carousel below.
Growing the Knowledge of Detection and Treatment of Infantile Spasms: Martina Bebin, MD, MPA
December 5th 2022The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center provided perspective on the strides made with detection and treatment of infantile spasms. [WATCH TIME: 3 minutes]
Jacksonian Epilepsy and the Jacksonian March: R. Edward Hogan, MD
December 5th 2022The professor of neurology at Washington University in St. Louis, and the president of the American Epilepsy Society, shared his perspective on John Hughlings Jackson’s observations of epilepsy in the brain and how it can inform modern practice. [WATCH TIME: 5 minutes]
Transition to Adult Care Is Inconsistent for Patients With Dravet Syndrome, Survey Suggests
December 4th 2022A survey conducted in conjunction with the Dravet Syndrome Foundation suggests that many patients with DS do not undergo the transition of care from pediatric to adult neurology providers, with caregivers of those who did expressing some concerns about the process.
Broad Anti-inflammatory Approaches Feasible for Epilepsy: Nicholas Varvel, PhD
December 4th 2022The assistant professor in the department of pharmacology and chemical biology at Emory University School of Medicine spoke about immune cells in epilepsy based on his special lecture at the 2022 AES Annual Meeting. [WATCH TIME: 4 minutes]
Focal Epilepsy Diagnosis Delay Increases Suicidal Ideation Among Youth
December 4th 2022A retrospective observation study presented as a poster at the 2022 AES annual meeting revealed that youth with focal epilepsy were more at risk for suicidal ideation when there is a delay in receiving a diagnosis.
Wide Variety Exists for First Antiseizure Medication Prescriptions in Children With Epilepsy
December 4th 2022Data from the Pediatric Epilepsy Learning Healthcare System suggest that a variety of factors—including age, preference, insurance, and demographics—affect physician selection of antiseizure medications, with little standardization among this population.
New Prospective Data on Patients With Dravet Syndrome Inform Outcome Measurements in Trials
December 3rd 2022Data from the BUTTERFLY study of 36 children with Dravet syndrome have provided 12-month measurements of neurodevelopment, clinical status, quality of life, and executive function. Investigators expressed that these data will help inform future trial outcome measures.
The Pediatric Epilepsy Learning Healthcare System Provides Big Data to Answer Big Questions
December 3rd 2022Zachary Grinspan, MD, MS, a pediatric epilepsy specialist at Weill Cornell Medicine, in New York City, spoke about the analysis of large amounts of data on pediatric epilepsy at the 2022 American Epilepsy Society Annual Meeting.
Using Semiology to Improve Epilepsy Clinical Trials: Jacqueline French, MD
December 3rd 2022The professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation discussed the critical need to ensure the proper classification of seizures when enrolling patients in clinical trials. [WATCH TIME: 4 minutes]
Expanding Neuropalliative Care to New Disease States: Benzi Kluger, MD, MS
November 28th 2022The president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]
Cell Therapy NRTX-1001 Shows Significant Effect on Drug-Resistant Epilepsy in Early Data
November 22nd 2022NRTX-1001, an injectable suspension of high-purity inhibitory neurons, is currently being assessed in a phase 1/2 trial that includes a dose-escalation period comprising of 10 individuals with mesial temporal lobe epilepsy.